Resources


December 10, 2019

iBio Introduces FastGlycaneering Development Service™ to Power Recombinant Protein Production

NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today unveiled the FastGlycaneering Development Service™, which includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. ...

Continue Reading

December 3, 2019

iBio Joins Manufacturing USA’s Tissue Biofabrication Initiative

iBio to Support the 3D Bioprinting Industry with Enabling Biomaterials NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it is now part of a new public-private Manufacturing USA initiative, the Advanced ...

Continue Reading

September 18, 2019

iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage

NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into the initial Statement of Work (“SOW1”) under its Memorandum of Understanding (“MOU”) with AzarGen ...

Continue Reading

August 27, 2019

iBio and CC-Pharming Expand Business Collaboration in China

iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has expanded the scope of its business venture with CC-Pharming Ltd. by granting it an exclusive, royalty-bearing commercial license to iBio’s bio-better rituximab (“iBio Rituximab”) product ...

Continue Reading

August 19, 2019

iBio Inks 3D Bioprinting Agreement

iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a subsidiary of United Therapeutics Corporation (NASDAQ:UTHR), to produce recombinant human collagen ...

Continue Reading
1 2 3 4